Centers | ||
|
|
|
EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
GSK and MD Anderson to co-develop new cancer therapeuticsGlaxoSmithkline and MD Anderson Cancer Center entered into a co-development and license agreement to develop antibody based therapeutics to treat cancer. Under this agreement MD Anderson grants exclusive rights to antibodies developed during the... View all Yale to Partner with Gilead to Further Cancer ResearchYale and Gilead have entered into a multi-year research collaboration to develop new treatments against cancer. Gilead will provide $40million in funding for research and other infrastructure support for the initial four years. The agreement can... View all Brigham & Woman's Hospital and Sanofi to Partner in Type 1 Diabetes SpaceSanofi and Brigham & Woman's Hospital an affiliate of Harvard University have entered into a joint collaboration to develop new drugs based on novel immunomodulatory approach to treat Type 1 Diabetes. Scientists from both groups will be... View all |
No EVENTS for listing |
No Job Posts |
